Trial · NCT05061771
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Achievement of Complete Disease Remission | weeks 16 - 24 | Proportion of patients in Complete Disease Remission |
| Secondary | Cumulative oral corticosteroid, OCS, during treatment | Randomization to 24 weeks | Cumulative OCS used during treatment |
| Secondary | Proportion of patients requiring rescue therapy | Randomization to 24 weeks | Proportion of patients requiring rescue therapy during the 24 weeks of treatment |
| Secondary | Achievement Partial Disease Remission | weeks 16 - 24 | Proportion of patients in Partial Disease Remission |
| Secondary | Time to onset of Complete Disease Remission | week 6 to 24 | Time (weeks) to onset of Complete Disease Remission |
| Secondary | Duration of Complete and Partial Disease Remission | week 6 to 24 | Duration (weeks) of Complete Disease Remission and Partial Disease Remission |
| Secondary | Investigator Global Assessment (IGA) score | weeks 6 - 24 | Proportion of patients with Investigator Global Assessment (IGA) score of 0 or 1 |
| Secondary | Adverse Events | Day 1 to Week 28 | Frequency, type and relationship of AEs to treatment |
| Secondary | Steroid-related AEs | Day 1 to Week 28 | Incidence of steroid-related AEs |
| Secondary | Dermatology Life Quality Index (DLQI) | Randomisation to week 24 | Change from baseline in Dermatology Life Quality Index (DLQI) |
| Secondary | Incidence of treatment-emergent anti-drug antibody (ADA) responses and titre and neutralising potential assessed in vitro at baseline and every 4 weeks | Day 1 to Week 28 | Incidence of treatment-emergent anti-drug antibody (ADA) responses and titre and neutralising potential assessed in vitro at baseline and then every 4 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05061771/registered